From Medicineworld.org: New Therapy For Advanced-Stage Lymphoma
Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.
Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.
Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.
Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.
Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.
Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.
New Therapy For Advanced-Stage Lymphoma
Follicular lymphomaOncologists have been stymied by how to treat some patients with lymphoma who do not respond to new, targeted therapies. A study by researchers at the University of Rochester Medical Center and other institutions shows there might be a new drug that combats indolent non-Hodgkin's lymphoma when others fail.
Bendamustine, an agent that attacks cancer cells' DNA forcing them to self-destruct and disrupting the cell-division cycle, was given to 77 patients, most of whom had advanced follicular lymphoma, who did not respond to rituximab, considered the wonder-drug for lymphomas, and 74 percent of them responded, including 35 percent who were brought into remission.
"This is very exciting because it's the first study of chemotherapy for a class of patients who didn't respond to rituximab and it provides an effective alternative for them," said Jonathan Friedberg, M.D., of the James P. Wilmot Cancer Center at the University of Rochester Medical Center. He presented results of the international study today at the American Society of Hematology's annual meeting in Atlanta.
"It's unusual to see this kind of response in patients so far along in the course of their disease, particularly since they previously did not response to other alkylators and were relapsed from rituximab," said Friedberg, associate director of lymphoma clinical research at Wilmot.
About half of follicular lymphoma patients respond to rituximab as a single agent, and a standard therapy is with a chemotherapy combination called CHOP. Doctors have struggled with how to treat people who don't respond, or stop responding to that treatment. It's common for patients with follicular lymphoma to relapse multiple times during the typically 10-year natural progression of the disease.
"Typically these patients need several different therapies over the years and none of them are curative. This data suggests that bendamustine will add to our therapy options for this disease," Friedberg said.
The phase II study focused on heavily pre-treated, older patients with Stage 3 or Stage 4 disease who were treated at 17 centers between 2004-05.
The 74 percent response rate included 35 percent of the patients in total remission, along with 39 percent who had a partial response. Seven percent of the patients' disease was stable, and another 16 percent had disease progression. The average length of response was six months.
Bendamustine is being developed by Cephalon Oncology, which funded the clinical trial. Participating sites included Georgetown University, University of Alabama at Birmingham, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, University of Virginia, Pacific Oncology and Hematology Associates and Desert Regional Medical Center in California, and Queen Elizabeth II Health Science Center and Ottawa Hospital in Canada.
A phase III study of bendamustine is underway for patients with indolent non-Hodgkin's lymphoma who are resistant to rituximab. The Wilmot Cancer Center is accruing patients for this study.
Source: University of Rochester Medical Center
Did you know?
Oncologists have been stymied by how to treat some patients with lymphoma who do not respond to new, targeted therapies. A study by researchers at the University of Rochester Medical Center and other institutions shows there might be a new drug that combats indolent non-Hodgkin's lymphoma when others fail.
Medicineworld.org: New Therapy For Advanced-Stage Lymphoma
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.